$CVKD
Cadrenal Therapeutics, Inc. Stock $cvkd

$cvkd Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024021133 Filed on March 11, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue			$220.1K
YoY Change
Gross Profit			-$220.1K
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.126M	$902.1K	$3.550M
YoY Change		-60.91%	53.82%
% of Gross Profit
Research & Development	$629.0K	$361.1K	$4.081M
YoY Change	581.83%	-8.08%	938.88%
% of Gross Profit
Depreciation & Amortization	$597.00	$1.980K	$1.980K
YoY Change	214.21%	55.91%	55.91%
% of Gross Profit
Operating Expenses	$1.756M	$1.264M	$7.633M
YoY Change	-58.2%	-53.22%	182.53%
Operating Profit	-$1.756M		-$7.633M
YoY Change	-58.2%
Interest Expense	$92.33K	$119.8K	$15.90K
YoY Change	2512.62%	-102.98%	-100.4%
% of Operating Profit
Other Income/Expense, Net	$92.33K		-$724.2K
YoY Change	-90.51%
Pretax Income	-$1.663M	-$1.144M	-$8.357M
YoY Change		-82.96%	24.47%
Income Tax
% Of Pretax Income
Net Earnings	-$1.663M	-$1.144M	-$8.357M
YoY Change	-67.85%	-82.96%	24.47%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.10		-$0.62
Diluted Earnings Per Share	-$0.10	-$1.07	-$0.62
COMMON SHARES
Basic Shares Outstanding	16.01M shares	13.02M shares	13.49M shares
Diluted Shares Outstanding	16.01M shares		13.49M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.566M	$8.403M	$8.403M
YoY Change		25682.45%	25682.45%
Cash & Equivalents	$6.566M	$8.403M
Short-Term Investments
Other Short-Term Assets	$461.6K	$89.67K	$89.67K
YoY Change		-87.1%	-87.1%
Inventory
Prepaid Expenses	$293.8K	$89.67K
Receivables
Other Receivables
Total Short-Term Assets	$7.028M	$8.492M	$8.492M
YoY Change	58.31%	1067.15%	1067.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.690K	$2.287K	$23.29K
YoY Change	105.35%	125.77%	-47.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.792K	$3.792K	$3.790K
YoY Change	0.03%	-36.66%	-36.73%
Total Long-Term Assets	$20.40K	$27.08K	$27.08K
YoY Change	-52.33%	-46.46%	-46.45%
TOTAL ASSETS
Total Short-Term Assets	$7.028M	$8.492M	$8.492M
Total Long-Term Assets	$20.40K	$27.08K	$27.08K
Total Assets	$7.048M	$8.519M	$8.519M
YoY Change	57.26%	994.77%	994.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$400.4K	$167.3K	$167.3K
YoY Change	234.85%	-58.68%	-58.68%
Accrued Expenses	$440.8K	$638.2K	$621.5K
YoY Change	70.25%	-26.1%	-29.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$856.3K	$826.9K	$826.9K
YoY Change	113.21%	-38.04%	-38.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$856.3K	$826.9K	$826.9K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$856.3K	$826.9K	$826.9K
YoY Change	105.45%	-86.94%	-86.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$16.73M	-$15.07M
YoY Change	40.77%	124.47%
Common Stock	$22.93M	$22.76M
YoY Change	195487.95%	277710.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.192M	$7.692M	$7.692M
YoY Change
Total Liabilities & Shareholders Equity	$7.048M	$8.519M	$8.519M
YoY Change	57.26%	994.77%	994.78%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.663M	-$1.144M	-$8.357M
YoY Change	-67.85%	-82.96%	24.47%
Depreciation, Depletion And Amortization	$597.00	$1.980K	$1.980K
YoY Change	214.21%	55.91%	55.91%
Cash From Operating Activities	-$1.836M	-$3.530M	-$3.530M
YoY Change	29.98%	398.68%	193.03%
INVESTING ACTIVITIES
Capital Expenditures			$3.254K
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$3.250K	-$3.250K
YoY Change		42.54%	42.54%
Cash From Investing Activities		-$3.250K	-$3.254K
YoY Change		42.54%	42.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$298.00	11.90M	$11.90M
YoY Change	-99.99%	1642.44%	860.24%
NET CHANGE
Cash From Operating Activities	-$1.836M	-3.530M	-$3.530M
Cash From Investing Activities		-3.250K	-$3.254K
Cash From Financing Activities	$298.00	11.90M	$11.90M
Net Change In Cash	-$1.836M	8.370M	$8.370M
YoY Change	-145.95%	-31030.97%	25582.46%
FREE CASH FLOW
Cash From Operating Activities	-$1.836M	-$3.530M	-$3.530M
Capital Expenditures			$3.254K
Free Cash Flow			-$3.534M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41596
CY2023	dei	Entity Registrant Name EntityRegistrantName	CADRENAL THERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	88-0860746
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	822 A1A North
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 306
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Ponte Vedra
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32082
CY2023	dei	City Area Code CityAreaCode	(904)
CY2023	dei	Local Phone Number LocalPhoneNumber	300-0701
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	CVKD
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	6399323	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16008469	shares
CY2023	dei	Auditor Firm AuditorFirmId	100
CY2023	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2023	dei	Auditor Location AuditorLocation	East Brunswick, New Jersey
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8402500	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32586	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	89673	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	22715	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	672295	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	8492173	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	727596	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2287	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1013	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20998	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	43578	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3792	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5987	usd
CY2023Q4	us-gaap	Assets Assets	8519250	usd
CY2022Q4	us-gaap	Assets Assets	778174	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	167319	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	404897	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	638206	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	863564	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21350	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	22288	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	43728	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	826875	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1334477	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	110380	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4379944	usd
CY2022Q4	cvkd	Accrued Interest Non Current AccruedInterestNonCurrent	40213	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21350	usd
CY2023Q4	us-gaap	Liabilities Liabilities	826875	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6329324	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13022754	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13022754	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8193875	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8193875	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	13022	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	8194	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	22750768	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1154985	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15071415	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6714329	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	7692375	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5551150	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8519250	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	778174	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3549514	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2307503	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4081349	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	392859	usd
CY2023	us-gaap	Depreciation Depreciation	1980	usd
	us-gaap	Depreciation Depreciation	1266	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	7632843	usd
	us-gaap	Operating Expenses OperatingExpenses	2701628	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-7632843	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2701628	usd
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	249092	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	863622	usd
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	21	usd
CY2023	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	3534	usd
	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	40213	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	13567	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	66913	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	216095	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3905596	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-740139	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-724243	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4012701	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8357086	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6714329	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13491980	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7890507	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5551150	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5408575	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1140700	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	4596039	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-6494916	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	250000	usd
CY2023	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	3000000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	108276	usd
CY2023	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	602105	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8357086	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	7692375	usd
	cvkd	Stock Issued During Period Value Of Founder Shares StockIssuedDuringPeriodValueOfFounderShares	7950	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	928049	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	51621	usd
	cvkd	Adjustments To Additional Paid In Capital Issuance Of Investor Warrants AdjustmentsToAdditionalPaidInCapitalIssuanceOfInvestorWarrants	175559	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6714329	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5551150	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8357086	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6714329	usd
CY2023	us-gaap	Depreciation Depreciation	1980	usd
	us-gaap	Depreciation Depreciation	1266	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	710381	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	928049	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	13567	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	66913	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	216095	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3905596	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-740139	usd
CY2023	cvkd	Lessee Operating Non Cash Lease Expense LesseeOperatingNonCashLeaseExpense	292	usd
CY2023	cvkd	Issuance Of Shares To Settle Asset Purchase Agreement IssuanceOfSharesToSettleAssetPurchaseAgreement	3000000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	66958	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	22715	usd
CY2023	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-672295	usd
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	672295	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2195	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5987	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-237578	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	404897	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-225645	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-40213	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3530323	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1204770	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3254	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2279	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3254	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2279	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1011964	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	219721	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7950	usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	6494916	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	250000	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	250000	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	5408575	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11903491	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1239635	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	8369914	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	32586	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32586	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8402500	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32586	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	47090	usd
CY2023	cvkd	Issuance Of Common Shares For Consulting Services IssuanceOfCommonSharesForConsultingServices	1140700	usd
CY2023	cvkd	Derecognition Of Derivative Liabilitiy DerecognitionOfDerivativeLiabilitiy	4596039	usd
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	51621	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	474349	usd
	cvkd	Issuance Of Investor Warrants IssuanceOfInvestorWarrants	175559	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8357086	usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	4682454	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3530323	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8402500	usd
CY2023Q4	cvkd	Workings Capital WorkingsCapital	7665298	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15071415	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of financial instruments, the fair value of common stock prior to our IPO, deferred tax assets and valuation allowance, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Credit and Other Risks and Uncertainties</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents. Cash is maintained at high credit quality financial institutions and, at times, balances may exceed federally insured limits. All interest-bearing and non-interest-bearing cash balances are insured up to $250,000 per depositor at each financial institution. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to a number of risks common for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product candidate, ability to obtain regulatory approval of its product candidate, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</span></p>
CY2023	us-gaap	Interest Income Deposit With Financial Institution Increase Decrease InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease	250000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023	us-gaap	Revenue Recognition Customer Acquisitions RevenueRecognitionCustomerAcquisitions	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Acquisitions</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development (“IPR&D”) asset, the IPR&D asset is only capitalized if it has an alternative future use other than in a particular research and development project. For an IPR&D asset to have an alternative future use: (a) the Company must reasonably expect that it will use the asset acquired in an alternative manner and anticipate economic benefit from that alternative use, and (b) the Company’s use of the asset acquired is not contingent on the further development of the asset subsequent to the acquisition date (that is, the asset can be used in an alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts allocated to IPR&D that have no alternative use are expensed to research and development. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.50	pure
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	8287843	usd
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	8287843	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4379944	usd
CY2022Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	4379944	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	165192	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	596131	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	605290	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	38075	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	93082	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	638206	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	863564	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	100000	usd
CY2023	us-gaap	Asset Acquisition Consideration Transferred AssetAcquisitionConsiderationTransferred	2000000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.35	pure
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	20095	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	200000	usd
CY2023	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	20095	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	220095	usd
CY2023Q1	us-gaap	Shares Issued SharesIssued	600000	shares
CY2022Q4	cvkd	Convertible Notes Payable Related Parties ConvertibleNotesPayableRelatedParties	550000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	107040	usd
CY2022Q4	us-gaap	Other Notes Payable OtherNotesPayable	442960	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	575000	usd
CY2022Q4	cvkd	Debt Issuance Costs1 DebtIssuanceCosts1	464620	usd
CY2022Q4	cvkd	Convertible Debt1 ConvertibleDebt1	110380	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	250000	usd
CY2022Q4	cvkd	Debt Issuance Costs2 DebtIssuanceCosts2	206272	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	43728	usd
CY2022Q4	us-gaap	Debt Current DebtCurrent	597068	usd
CY2023Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	15000	shares
CY2023	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.80	pure
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.60	pure
CY2023Q1	us-gaap	Stock Dividends Shares StockDividendsShares	1140700	shares
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	740139	usd
CY2023Q1	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	740139	usd
CY2022Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	125000	shares
CY2022Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	7500	usd
CY2022Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	514792	shares
CY2022Q2	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	450000	shares
CY2022Q3	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	50000	shares
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20998	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	43578	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21350	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	22288	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21350	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21350	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	43638	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	26555	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	4394	usd
CY2023	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	26003	usd
	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	4334	usd
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	22319	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	22319	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	969	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	21350	usd
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	7500000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one
CY2023Q1	cvkd	Gross Proceeds GrossProceeds	7000000	usd
CY2023Q1	us-gaap	Credit Derivative Liquidation Proceeds Monetary Amount CreditDerivativeLiquidationProceedsMonetaryAmount	5408575	usd
CY2023Q1	cvkd	Purchase An Aggregate Shares PurchaseAnAggregateShares	84000	shares
CY2023Q1	us-gaap	Shares Acquired Weighted Average Discount To Net Assets Percentage SharesAcquiredWeightedAverageDiscountToNetAssetsPercentage	0.06	pure
CY2023Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	6
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate	1.20	pure
CY2023Q3	cvkd	Combined Purchase Price Of Warrant CombinedPurchasePriceOfWarrant	1.7499
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7500000	usd
CY2023	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.0999	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	276500	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	7634001	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	250000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7660501	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2000000	shares
CY2023Q4	us-gaap	Shares Issued SharesIssued	685000	shares
CY2023	cvkd	Stock Options Granted Shares Term stockOptionsGrantedSharesTerm	P10Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0451	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y3M29D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.707	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1100000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.84
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y6M25D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4578000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	75000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.2
CY2023	cvkd	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingGranted	P9Y6M21D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1175000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.86
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M20D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	105000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	584724	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.77
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y6M21D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	10808	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1175000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.86
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y7M20D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	105000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.09
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	676479	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1	P1Y4M24D
CY2023Q1	cvkd	Stock Options Granted StockOptionsGranted	50000	shares
CY2023Q1	us-gaap	Shares Issued SharesIssued	77340	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	710381	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	928049	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8357086	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6714329	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13491980	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7890507	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8835501	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1376500	shares
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-8357086	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-6714329	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-8357086	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6714329	usd
CY2023	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-1754988	usd
	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-1410009	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-136314	usd
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-263978	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	27006	usd
	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	8910	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	3150	usd
	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	125248	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	17642	usd
CY2023	cvkd	Effective Income Tax Rate Reconciliation Derivative Liabilities EffectiveIncomeTaxRateReconciliationDerivativeLiabilities	141457	usd
	cvkd	Effective Income Tax Rate Reconciliation Derivative Liabilities EffectiveIncomeTaxRateReconciliationDerivativeLiabilities	1003603	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Settlements Other IncomeTaxReconciliationTaxSettlementsOther	47	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-1702000	usd
	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-536226	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1099000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	298000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	138000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	44000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	807000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	55000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction	5000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	137000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	135000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2186000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	532000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-53000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	5000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2181000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	479000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	4700000	usd
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	2700000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1200000	usd
CY2022Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	1200000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements State And Local EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal	0.80	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.50	pure
CY2023	cvkd	Uncertain Tax Benefit UncertainTaxBenefit	0.50	pure
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023Q4	cvkd	Accrued Interest Non Current AccruedInterestNonCurrent		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13491980	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7890507	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	cvkd	Lessee Operating Non Cash Lease Expense LesseeOperatingNonCashLeaseExpense		usd
	cvkd	Issuance Of Shares To Settle Asset Purchase Agreement IssuanceOfSharesToSettleAssetPurchaseAgreement		usd
CY2023	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet		usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
	cvkd	Issuance Of Common Shares For Consulting Services IssuanceOfCommonSharesForConsultingServices		usd
	cvkd	Derecognition Of Derivative Liabilitiy DerecognitionOfDerivativeLiabilitiy		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2022Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue		usd
CY2023Q4	cvkd	Convertible Notes Payable Related Parties ConvertibleNotesPayableRelatedParties		usd
CY2023Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet		usd
CY2023Q4	us-gaap	Other Notes Payable OtherNotesPayable		usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable		usd
CY2023Q4	cvkd	Debt Issuance Costs1 DebtIssuanceCosts1		usd
CY2023Q4	cvkd	Convertible Debt1 ConvertibleDebt1		usd
CY2023Q4	us-gaap	Notes Payable NotesPayable		usd
CY2023Q4	cvkd	Debt Issuance Costs2 DebtIssuanceCosts2		usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q4	us-gaap	Debt Current DebtCurrent		usd
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13491980	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7890507	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate		usd
	us-gaap	Income Tax Reconciliation Tax Settlements Other IncomeTaxReconciliationTaxSettlementsOther		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction		usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001937993

Files In Submission

Name	View Source	Status
0001213900-24-021133-index-headers.html	Edgar Link	pending
0001213900-24-021133-index.html	Edgar Link	pending
0001213900-24-021133.txt	Edgar Link	pending
0001213900-24-021133-xbrl.zip	Edgar Link	pending
cvkd-20231231.xsd	Edgar Link	pending
ea0201078-10k_cadrenal.htm	Edgar Link	pending
ea0201078ex19-1_cadrenal.htm	Edgar Link	pending
ea0201078ex21-1_cadrenal.htm	Edgar Link	pending
ea0201078ex23-1_cadrenal.htm	Edgar Link	pending
ea0201078ex31-1_cadrenal.htm	Edgar Link	pending
cvkd-20231231_cal.xml	Edgar Link	unprocessable
cvkd-20231231_def.xml	Edgar Link	unprocessable
cvkd-20231231_lab.xml	Edgar Link	unprocessable
cvkd-20231231_pre.xml	Edgar Link	unprocessable
ea0201078-10k_cadrenal_htm.xml	Edgar Link	completed
ea0201078ex31-2_cadrenal.htm	Edgar Link	pending
ea0201078ex32-1_cadrenal.htm	Edgar Link	pending
ea0201078ex32-2_cadrenal.htm	Edgar Link	pending
ea0201078ex97-1_cadrenal.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img_001.jpg	Edgar Link	pending
img_002.jpg	Edgar Link	pending
img_003.jpg	Edgar Link	pending
img_004.jpg	Edgar Link	pending
img_005.jpg	Edgar Link	pending
img_006.jpg	Edgar Link	pending
img_007.jpg	Edgar Link	pending
img_008.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVKD
Cadrenal Therapeutics, Inc. Stock $cvkd

2024 Q1 Form 10-K Financial Statement

#000121390024021133 Filed on March 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVKD Cadrenal Therapeutics, Inc. Stock $cvkd

2024 Q1 Form 10-K Financial Statement

#000121390024021133 Filed on March 11, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVKD
Cadrenal Therapeutics, Inc. Stock $cvkd